journal article·2018-11-05Open access

Assessment of synergistic effect of combining hyperthermia with irradiation and calcium carbonate nanoparticles on proliferation of human breast adenocarcinoma cell line (MCF-7 cells)

Nasrollah Jabbari, Leila Zarei, Hadi Esmaeili Govarchin Galeh, Bahman Mansori Motlagh

Abstract

The present study was undertaken to evaluate the synergistic effect of combining hyperthermia with irradiation and calcium carbonate nanoparticles (CC NPs) on proliferation of MCF-7 cells. The cells were randomly allocated to 19 groups: one negative control, three positive controls and 15 treatment groups. MCF-7 cells were treated with three concentrations of CC NPs (50, 100 and 150 μg/mL), gamma radiation (200 cGy), hyperthermia (41 °C for 1 h) and three concentrations of doxorubicin (200, 400 and 800 nm) and incubated at 37 °C for 24 h. Then the cell viability, the percentage of apoptosis and the levels of caspase-3, -8 and -9 proteins were measured. The results indicated that the combination group (150 µg/mL CC NPs + thermoradiotherapy) had a significant (p < .001) decrease in cell viability (48.65 ± 4.8%) and a significant (p < .001) increase in apoptosis percentage (45 ± 1.63%) of MCF-7 cells, as compared with the negative control and most of the other treatment groups. Moreover, a significant (p < .05) increase was observed in the activity of caspase-3 and caspase-9. Our findings revealed that CC NPs in combination with irradiation and hyperthermia could significantly reduce the cell viability and enhance the apoptosis of the MCF-7 breast cancer cells, the same as doxorubicin anti-cancer drug.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Radiation Therapy and Dosimetry · Ultrasound and Hyperthermia Applications · Effects of Radiation Exposure

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Solid Tumor Research Center, Urmia University of Medical Sciences, Urmia, Iran

References (44)

Show source-provided references
1. 10.1200/JCO.2013.54.225810.1200/JCO.2013.54.2258 ↗
2. 10.1016/j.clon.2005.11.01110.1016/j.clon.2005.11.011 ↗
3. 10.1371/journal.pone.015882810.1371/journal.pone.0158828 ↗
4. 10.3322/caac.2120910.3322/caac.21209 ↗
5. 10.3390/cancers303327910.3390/cancers3033279 ↗
6. 10.4155/tde.11.7210.4155/tde.11.72 ↗
7. Hall EJ · 2011
8. Jabir NR · Int J Nanomedicine · 2012 · 7 · 4391
9. 10.1259/bjr.2015017110.1259/bjr.20150171 ↗
10. 10.1259/bjr.2015017010.1259/bjr.20150170 ↗
11. 10.1517/17425247.2015.104953010.1517/17425247.2015.1049530 ↗
12. Elengoe A · J Biotechnol Lett · 2013 · 4 · 45
13. 10.3109/10717544.2014.91676510.3109/10717544.2014.916765 ↗
14. Akhtar MJ · Int J Nanomedicine · 2012 · 7 · 845
15. Chung H · Appl Biol Sci · 2013 · 110 · 7625
16. 10.1080/21691401.2017.134794110.1080/21691401.2017.1347941 ↗
17. Florento L · Int J Biomed Sci · 2012 · 8 · 7610.59566/IJBS.2012.8076 ↗
18. 10.1080/21691401.2017.140801910.1080/21691401.2017.1408019 ↗
19. 10.1080/21691401.2016.120225710.1080/21691401.2016.1202257 ↗
20. 10.1111/jcmm.1218810.1111/jcmm.12188 ↗
21. 10.2147/IJN.S8395310.2147/IJN.S83953 ↗
22. 10.1080/21691401.2017.129064310.1080/21691401.2017.1290643 ↗
23. Rupnow BA · Cancer Res · 1998 · 58 · 1779
24. 10.1038/sj.onc.120481510.1038/sj.onc.1204815 ↗
25. 10.3109/0284186740912988010.3109/02841867409129880 ↗
26. 10.5772/5579510.5772/55795 ↗
27. 10.18632/oncotarget.2167810.18632/oncotarget.21678 ↗
28. 10.3390/ijms1801012010.3390/ijms18010120 ↗
29. Liu G · Int J Nanomedicine · 2015 · 10 · 6075
30. 10.1016/j.biomaterials.2012.05.04710.1016/j.biomaterials.2012.05.047 ↗
31. Su XY · Cancer Biol Med · 2014 · 11 · 86
32. 10.1016/j.canlet.2014.02.00610.1016/j.canlet.2014.02.006 ↗
33. 10.1667/RR1984.110.1667/RR1984.1 ↗
34. 10.1259/bjr/5944883310.1259/bjr/59448833 ↗
35. 10.1016/j.rpor.2010.09.00110.1016/j.rpor.2010.09.001 ↗
36. 10.1007/BF0270448110.1007/BF02704481 ↗
37. 10.1016/j.radphyschem.2014.04.03310.1016/j.radphyschem.2014.04.033 ↗
38. 10.4236/wjnse.2012.2100510.4236/wjnse.2012.21005 ↗
39. 10.15171/apb.2015.04910.15171/apb.2015.049 ↗
40. 10.1186/1756-9966-30-8710.1186/1756-9966-30-87 ↗
41. Baharara J · Avicenna J Med Biotechnol · 2016 · 8 · 75
42. 10.3390/molecules2002269310.3390/molecules20022693 ↗
43. 10.1186/1471-2121-14-3210.1186/1471-2121-14-32 ↗
44. 10.1016/j.colsurfb.2016.02.04310.1016/j.colsurfb.2016.02.043 ↗